cGxP.wire https://validator.w3.org/feed/docs/rss2.html Seaport Therapeutics Begins Phase 2a GlyphAgo Trial Arrowhead Wins FDA STAR Pilot Entry for Plozasiran Matchpoint Therapeutics Raises $150M Series B for Pipeline Arvinas Reports ARV-102 Phase 1 Parkinson’s Data VERAXA Advances FDA-Aligned Human-Relevant Models for R&D Shionogi to Acquire IntraBio for $2B Rare Disease Growth BillionToOne Northstar Response Shows Strong Cancer Monitoring Data CHARM Therapeutics Doses First Patient in CHM-029 AML Trial REVA Medical Presents MOTIV Scaffold Results at VIVA26 QIAGEN Expands AI-Powered Bioinformatics and Drug Discovery Nurix Begins Phase 1b/2 Bexobrutideg Combination Study in CLL PulseSight Reports Early PST-611 Data in Geographic Atrophy BridgeBio Wins FDA Priority Review for Oral Infigratinib SCYNEXIS Reports Phase 1 Results for SCY-770 Saluda Medical Launches CAP24 Paddle Lead Across U.S. Kairos Pharma Reports Positive Phase 2 ENV-105 Data GigHz Study Finds 76.5% of FDA AI Devices in Radiology RougeTx Launches with $58M Series A for HHT Therapy Telix Pixclara U.S. Commercial Availability Begins Alora Pharmaceuticals Highlights RELEXXII for ADHD Care Cala Launches Next-Generation TAPS Wearable Nationwide ViiV Healthcare’s Cabenuva Shows Superior HIV Suppression DarioHealth Reports Healthcare Cost Savings in Aon Review Beactica Advances BEA-28 as First-in-Class TEAD Degrader Lundbeck Advances Lu AF28996 in Parkinson’s Phase II TranspireBio Completes Phase 1 Study of Springboard Inhaler Nanoscope Therapeutics Presents MCO-010 Data at AAO 2026 Veeva DQS Advances Clinical Data Quality Across 1,000 Studies Viking Therapeutics Begins VK2735 Oral Maintenance Trial Mozart Therapeutics Advances MTX-101 in Type 1 Diabetes OKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain Quoin Pharmaceuticals QRX003 Paper Accepted for Publication Regeneron Presents New Cancer and Cancer-Associated Thrombosis Data at ESMO 2026 Nurix Therapeutics Extends Gilead Oncology Research Collaboration for Two More Years Marea Therapeutics Doses First Patient in Phase 2 Trial of MAR002 for Acromegaly Rani Therapeutics’ RaniPill Platform Accepted into FDA Emerging Technology Program vTv Therapeutics Completes Phase 3 CATT1 Enrollment for Cadisegliatin in Type 1 Diabetes Revolution Medicines Begins Phase 3 RASolute 309 Trial for RAS G12D Pancreatic Cancer Capricor Reports Positive Deramiocel Data in DMD Idorsia Highlights Aprocitentan Data in Obesity and CKM Hypertension Click Therapeutics Gains FDA Clearance for Motivista Smith+Nephew Launches CARTIHEAL AGILI-C in Europe Genmab and AbbVie Report Positive Epcoritamab Phase 3 Results GE HealthCare to Acquire SOFIE in $945M Radiopharma Deal ORIC-259 Advances Toward Clinical Development With Cancer Research UK Equillium Clears Australian Path for EQ504 Phase 1 Trial Korro Doses First Patients in Phase 1/2 Trial of KRRO-121 Curia Invests $28 Million to Expand Sterile API Manufacturing AHN Launches Clinical Trial of Novel PAH Therapy GRAIL Presents New Galleri Data at EDCC and ESMO 2026